Vertigo Benign PositionalNCT07749573
The Effect of Chewing Gum on Dizziness in Patients Diagnosed With Posterior Canal Benign Paroxysmal Positional Vertigo in the Emergency Department
A study testing Dimenhydrinate and Sugar-Free Mint-Flavored Chewing Gum in people with Vertigo Benign Positional and Dizziness, run by Ankara Ataturk Sanatorium Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Dizziness is a common reason for emergency department visits. Posterior canal benign paroxysmal positional vertigo (BPPV) is one of the most frequent causes of peripheral vertigo. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Vertigo Benign Positional, Dizziness
- What is being tested?
- Dimenhydrinate and Sugar-Free Mint-Flavored Chewing Gum
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 88 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2026to 1 Dec 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18-65 years
- Duration of dizziness complaint less than 24 hours
- Posterior canal BPPV diagnosis confirmed by the emergency physician via the Dix-Hallpike test
- Intravenous administration of 50 mg dimenhydrinate in 100 cc 0.9% NaCl initiated by the responsible emergency physician
- Symptomatic dizziness with VAS ≥ 4
- Alert, cooperative, and able to chew gum
- Willingness to participate and provision of written informed consent
Who cannot join
- Findings suggestive of central vertigo (vertical nystagmus, diplopia, ataxia, hemiparesis, focal neurological deficit, etc.)
- Pregnancy
- Known gum intolerance, history of allergy to gum or its excipients, temporomandibular joint dysfunction, significant tooth loss, use of dentures or removable prosthetics that would prevent chewing
- Altered level of consciousness
- Central pathology detected on investigations performed during the visit
- Hemodynamic and/or respiratory instability
Show all 11Show fewer
- Diagnosis other than posterior canal BPPV as the cause of vertigo
- Treatment other than pharmacological therapy planned or already administered by the responsible emergency physician
- Active vomiting at the time of enrollment
- Severe dizziness with VAS ≥ 8 (excluded due to high likelihood of requiring additional treatment, risk of protocol deviation, and safety concerns regarding gum chewing)
- Patients who initially consented but subsequently wish to withdraw from the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Ankara Atatürk Sanatorium Training and Research Hospital
Ankara
Şeref Kerem Çorbacıoğlu, +905437656176, serefkeremcorbacioglu@gmail.com
About this study
Official title: The Effect of Chewing Gum in Addition to Standard Treatment on Dizziness in Patients Diagnosed With Posterior Canal Benign Paroxysmal Positional Vertigo in the Emergency Department: A Randomized Controlled Clinical Trial
Dizziness is a common reason for emergency department visits. Posterior canal benign paroxysmal positional vertigo (BPPV) is one of the most frequent causes of peripheral vertigo. Intravenous dimenhydrinate is among the standard treatments administered in the emergency setting; however, this and similar drug classes may cause sedation and delay central compensation.
This study tests the hypothesis that chewing gum may modulate the vestibular system via trigeminal and cervical neuromuscular pathways, thereby reducing dizziness and nausea symptoms. Patients diagnosed with posterior canal BPPV who are started on intravenous dimenhydrinate will be randomly assigned to two groups: the intervention group will chew sugar-free mint-flavored gum for 20 minutes in addition to standard treatment, while the control group will receive standard treatment only. Dizziness and nausea severity will be assessed using VAS at baseline, 20 minutes, and 60 minutes.
- Conditions
- Vertigo Benign Positional, Dizziness
- Being tested
- Dimenhydrinate, Sugar-Free Mint-Flavored Chewing Gum
- Medical subject headings
- Benign Paroxysmal Positional Vertigo, Dizziness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DimenhydrinateDrug
Dimenhydrinate 50 mg diluted in 100 mL of 0.9% sodium chloride administered intravenously as standard treatment for posterior canal benign paroxysmal positional vertigo in the emergency department.
Sugar-Free Mint-Flavored Chewing GumBehavioural
Participants chew one piece of sugar-free mint-flavored chewing gum under observation for 20 minutes, starting simultaneously with standard intravenous treatment.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Active comparator | Patients receive only the standard treatment initiated by the responsible emergency physician: 50 mg dimenhydrinate in 100 cc 0.9% NaCl administered intravenously Receives: Drug: Dimenhydrinate |
| Intervention Group | Experimental | In addition to standard treatment (50 mg dimenhydrinate in 100 cc 0.9% NaCl IV), patients receive sugar-free mint-flavored chewing gum simultaneously with the start of treatment and chew it under observation for 20 minutes. Receives: Drug: Dimenhydrinate; Behavioral: Sugar-Free Mint-Flavored Chewing Gum |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in dizziness Visual Analog Scale score from baseline to 20 minutes
The primary outcome is the change in dizziness severity measured using a 10-cm Visual Analog Scale, ranging from 0 (no dizziness) to 10 (worst imaginable dizziness), with higher scores indicating greater dizziness severity, between baseline and 20 minutes after treatment initiation.
Measured: Baseline and 20 minutes after treatment initiation
Secondary outcomes (1)
Nausea Visual Analog Scale score at 20 minutes
Nausea severity will be assessed 20 minutes after treatment initiation using a 10-cm Visual Analog Scale, ranging from 0 (no nausea) to 10 (worst imaginable nausea), with higher scores indicating greater nausea severity.
Measured: 20 minutes after treatment initiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Sep 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vertigo Benign PositionalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ankara Ataturk Sanatorium Training and Research Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Şeref Kerem Çorbacıoğlu, Ankara Ataturk Sanatorium Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07749573
- Sponsor's protocol ID
- 2024-KAEK-24/43
- Status last verified
- Aug 2026
- First submitted
- 23 Jul 2026
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No